Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib in Myelofibrosis Previously Treated With Ruxolitinib
NCT01523171Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of fedratinib in myelofibrosis (MF), sponsored by Bristol Myers Squibb. Started Apr 2012; status: terminated.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01523171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01523171.